Sitagliptin and heart failure hospitalization in patients with type 2 diabetes

被引:5
|
作者
Tseng, Chin-Hsiao [1 ,2 ,3 ]
机构
[1] Natl Taiwan Univ, Coll Med, Dept Internal Med, Taipei, Taiwan
[2] Natl Taiwan Univ Hosp, Div Endocrinol & Metab, Dept Internal Med, Taipei, Taiwan
[3] Natl Hlth Res Inst, Div Environm Hlth & Occupat Med, Zhunan, Taiwan
关键词
heart failure; hospitalization; incretin; sitagliptin; Taiwan; THYROID-CANCER RISK; CLINICAL-TRIALS; RETROSPECTIVE COHORT; INHIBITORS; TAIWANESE; METFORMIN; MELLITUS;
D O I
10.18632/oncotarget.10507
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study evaluated the risk of heart failure hospitalization in a 1: 1 matched pair sample of sitagliptin ever and never users derived from the Taiwan's National Health Insurance. A total of 85,859 ever users and 85,859 never users matched on 8 digits of propensity score were followed for the first event of heart failure hospitalization until December 31, 2011. The treatment effect (for ever versus never users, and for tertiles of cumulative duration of therapy) was estimated by Cox regression incorporated with the inverse probability of treatment weighting using propensity score. Additionally, adjusted hazard ratios for heart failure were estimated for the baseline characteristics in sitagliptin ever users. Results showed that the incidence of heart failure hospitalization was 1,020.16 and 832.54 per 100,000 person-years, respectively, for ever and never users, with an overall hazard ratio (95% confidence intervals) of 1.262 (1.167-1.364). While compared to never users, the respective hazard ratio for the first, second, and third tertile of cumulative duration < 3.7, 3.7-10.3 and > 10.3 months was 2.721 (2.449-3.023), 1.472 (1.318-1.645) and 0.515 (0.447-0.594). Older age, longer diabetes duration, male sex, and use of insulin, sulfonylurea, calcium channel blockers, aspirin, ticlopidine, clopidogrel and dipyridamole were significantly associated with a higher risk in sitagliptin users, but dyslipidemia and use of metformin and statin were protective. In conclusion, sitagliptin increases the risk of heart failure hospitalization within one year of its use, but reduces the risk thereafter. Some factors predisposing to sitagliptin-related heart failure are worthy of attention in clinical practice.
引用
收藏
页码:62687 / 62696
页数:10
相关论文
共 50 条
  • [41] Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure
    Granberry, Mark C.
    Hawkins, Jason B.
    Franks, Amy M.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2007, 64 (09) : 931 - 936
  • [42] Metabolic Inflexibility in Patients with Type 2 Diabetes and Heart Failure
    Hoskova, Eva
    Kopecky, Jan, Jr.
    Veleba, Jiri
    Velebova, Katerina
    Melenovsky, Vojtech
    Pelikanova, Terezie
    DIABETES, 2019, 68
  • [43] Chronic heart failure in patients with type-2 diabetes
    Strongin, LG
    Pochinka, IG
    KARDIOLOGIYA, 2005, 45 (02) : 33 - 36
  • [44] Association Between Hospitalization for Heart Failure and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes: An Observational Study
    Fu, Alex Z.
    Johnston, Stephen S.
    Ghannam, Ameen
    Tsai, Katherine
    Cappell, Katherine
    Fowler, Robert
    Riehle, Ellen
    Cole, Ashley L.
    Kalsekar, Iftekhar
    Sheehan, John
    DIABETES CARE, 2016, 39 (05) : 726 - 734
  • [45] Major Influence of Diabetes on Hospitalization for Heart Failure in Patients With Ischemic Heart Diseases
    Nagoshi, Tomohisa
    CIRCULATION JOURNAL, 2020, 84 (03) : 382 - 383
  • [46] Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus
    Wolsk, Emil
    Claggett, Brian
    Diaz, Rafael
    Dickstein, Kenneth
    Gerstein, Hertzel C.
    Kober, Lars
    Lawson, Francesca C.
    Lewis, Eldrin F.
    Maggioni, Aldo P.
    McMurray, John J. V.
    Probstfield, Jeffrey L.
    Riddle, Matthew C.
    Solomon, Scott D.
    Tardif, Jean-Claude
    Pfeffer, Marc A.
    CIRCULATION, 2017, 136 (16) : 1560 - 1562
  • [47] Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS
    Michael A. Nauck
    Darren K. McGuire
    Karen S. Pieper
    Yuliya Lokhnygina
    Timo E. Strandberg
    Axel Riefflin
    Tuncay Delibasi
    Eric D. Peterson
    Harvey D. White
    Russell Scott
    Rury R. Holman
    Cardiovascular Diabetology, 18
  • [48] Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS
    Nauck, Michael A.
    McGuire, Darren K.
    Pieper, Karen S.
    Lokhnygina, Yuliya
    Strandberg, Timo E.
    Riefflin, Axel
    Delibasi, Tuncay
    Peterson, Eric D.
    White, Harvey D.
    Scott, Russell
    Holman, Rury R.
    CARDIOVASCULAR DIABETOLOGY, 2019, 18 (01)
  • [49] Effect modifications on risk of hospitalization due to heart failure in type 2 diabetes patients receiving dapagliflozin versus empagliflozin
    Shao, Shih-Chieh
    Chang, Kai-Cheng
    Chen, Hui-Yu
    Chan, Yuk-Ying
    Yang, Yea-Huei Kao
    Lai, Edward Chia-Cheng
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 309 - 310
  • [50] Effect of sitagliptin on proteinuria in patients with type 2 diabetes-A renoprotective effect of sitagliptin
    Narimani, Rouhollah
    Kachuei, Ali
    Rezvanian, Hassan
    Feizi, Awat
    Poorpoone, Mohadese
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2021, 26 (01): : 35